Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study
Journal of Medical Virology · 2026-11 · 98 (11)
DOI: 10.1002/jmv.71190 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, online erschienen am 29.10.2026. Verfasst von Carolyn T Bramante und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of General Internal Medicine, University of MN Medical School, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Metformin, COVID-19, Hypoglycemic Agents, COVID-19 Drug Treatment. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Heart, Lung and Blood Institute.
Abstract (Originalsprache)
Our objective was to evaluate metformin prescribed at the time of SARS‐CoV‐2 infection on the risk of developing Long COVID (LC) in electronic health record data. We conducted a new user analysis of metformin prescribed within 6 days of documented infection with severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) versus experimental control: prescription for fluvoxamine, fluticasone, ivermectin, or montelukast. Inclusion criteria: a clinic visit in the 0–6 months and the 6–12 months before infection. Exclusion criteria: metformin or control within 12 months. Primary outcome: LC or death (LC/D), to address death as a competing risk, among patients prescribed drug within Days 0–6 of infection. LC was defined by diagnosis code or computable phenotype. We used entropy balancing to estimate the average treatment effect with a weighted log‐linear model. After weighting, there were 248 in the metformin and control groups; the average age was 53 (16); 16% were Black; and 16% were Hispanic. In the primary analysis, 10/248 (4.0%) in the metformin group developed LC/D versus 21/248 (8.5%) in the control group, adjusted risk ratio (aRR) 0.47 (95% CI 0.25–0.89, p = 0.02). For prescriptions on Days 0–1 relative to infection, aRR was 0.39 (95% CI 0.12–1.24); for prescriptions on Days 0–14, the aRR was 0.75 (95% CI 0.52–1.08). In this observational analysis, metformin prescribed within a week of documented SARS‐CoV‐2 infection was associated with a 53% lower risk of LC over 6 months than comparator medications. With the aRR of 0.47 (95% CI 0.25–0.89), any risk reduction between 75% and 11% is highly compatible with our data. This analysis of electronic health record diagnoses is important for the reproducibility of clinical trial results that ascertained the same outcome but via participant‐report.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of General Internal Medicine, University of MN Medical School, Minneapolis, Minnesota, USA.
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
- Division of Biostatistics and Health Data Science, University of Minnesota School of Public Health, Minneapolis, Minnesota, USA.
- Department of Medicine, Division of Endocrinology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
- Division of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina, USA.
- Division of Biostatistics, University of Virginia School of Data Science, Charlottesville, Virginia, USA.
ORCID-Profile: Carolyn T Bramante, Til Stürmer, Jared D Huling, John B Buse, Christopher Lindsell, Thomas Stewart, Steven G Johnson
Förderung
- NIDDK NIH HHS
- NCATS NIH HHS
- National Heart, Lung and Blood Institute
- NIA NIH HHS
- National Center for Advancing Translational Sciences
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institute on Aging
Zitieren
APA
Bramante, C. T., Stürmer, T., Huling, J. D., Buse, J. B., Lindsell, C., Stewart, T., Rothman, R. L., Sahner, D., Dunsmore, S. E., Topol, E., Wiggen, T. D., Makkar, S., Toler, A., Estepp, T., Johnson, S. G., & N3C Consortium (2026). Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study. Journal of Medical Virology, 98(11). https://doi.org/10.1002/jmv.71190
Vancouver
Bramante CT, Stürmer T, Huling JD, Buse JB, Lindsell C, Stewart T, et al. Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study. Journal of Medical Virology. 2026;98(11). doi:10.1002/jmv.71190
BibTeX
@article{Bramante2026,
author = {Bramante, Carolyn T and Stürmer, Til and Huling, Jared D and Buse, John B and Lindsell, Christopher and Stewart, Thomas and Rothman, Russell L and Sahner, David and Dunsmore, Sarah E and Topol, Eric and Wiggen, Talia D and Makkar, Steve and Toler, Andrew and Estepp, Taylor and Johnson, Steven G and N3C Consortium, N3C Consortium},
title = {Metformin at the Time of COVID‐19 Infection and Risk of Long COVID: A Target Trial Emulation Study},
journal = {Journal of Medical Virology},
year = {2026},
volume = {98},
number = {11},
doi = {10.1002/jmv.71190}
}
EUVIMED